The fourth quarter did not close as strong as the previous year. The greatest deviation, compared to the fourth quarter of last year, relates to the significantly lower earnings in business area Specialty Pharma due to increased competition on the British market for Melatonin. Business areas Assistive Tech and Medtech had stable sales but lower margins than in the comparison quarter of last year, and thereby, do not compensate for the lower earnings in Specialty Pharma. Margin is impacted e.g. by product mix and inventory write-downs, affecting all business areas in the quarter.

As a result, the Group estimates that revenues for the fourth quarter will amount to 474 MSEK, which corresponds to an increase of 4 percent compared to previous year. EBITA is expected to amount to 71 MSEK, which is 23 percent lower than previous year. Adjusted EBITA is expected to amount to 67 MSEK which is 27 percent lower than previous year.

Revenues for the business areas are expected to amount to 215 MSEK for Assistive Tech, 153 MSEK for Medtech and 106 MSEK for Specialty Pharma. Adjusted EBITA in the business areas are expected to amount to 48 MSEK for Assistive Tech, 19 MSEK for Medtech and 7 MSEK for Specialty Pharma.

"Demand is generally good but the year did not close result wise on the same high level as the previous year. The lower sales of Melatonin combined with product mix and inventory write-downs results in lower margin and result than previous year's strong fourth quarter. The quarter result is unsatisfactory but our view on the Group's nice development during the year and continued good opportunities remain unchanged", says Anders Dahlberg, MedCap CEO

The report for the fourth quarter will be published on January 31, 2025.

Stockholm January 16, 2025

MedCap AB (publ)

Anders Dahlberg, CEO